Kornimate/medical-research-clean huggingface dataset:
validation of an automatic analysis algorithm of the probability of glaucoma from optic disc images

Conditions: Glaucoma, Suspect; Glaucoma; Ocular Hypertension

Summary: clinical, cross-sectional and prospective study to assess the images of the posterior pole of the retina of patients from the glaucoma unit of the ioba and the hospital clínico universitario de valladolid during the period between may and december 2021. the aim of the project is to provide a sufficient number of images from posterior pole retinographies in patients with suspected glaucoma or with diagnosis of glaucoma in order to determine the sensitivity and specificity of an automatic glaucoma screening algorithm developed by the company transmural biotech s.l.


Eligibility criteria:
inclusion criteria: * primary open angle glaucoma or ocular hypertension * signed informed consent * visual field examination within the last 12 months exclusion criteria: * ocular or systemic pathologies that may interfere with the quality of the retinographic image or the results of the visual field * congenital anomalies of the papilla that seriously alter its structure * high ametropia (\> 10 diopters) * pharmacological mydriasis contraindication.

Keywords: deep learning diagnoses disease glaucoma retinographies
effect of calcium hypochlorite versus sodium hypochlorite as root canal irrigants on postoperative pain and bacterial reduction in mandibular premolars with necrotic pulps. .

Conditions: Intervention

Summary: this study aims to assess the effect of calcium hypochlorite versus sodium hypochlorite as root canal irrigants on postoperative pain and bacterial reduction in mandibular premolars with necrotic pulps.


Eligibility criteria:
inclusion criteria: 1. systematically healthy patient (asa i, ii). 2. age between 20 and 55 years 3. male or female. 4. mandibular premolar teeth having single canals diagnosed with pulp necrosis with asymptomatic apical periodontitis. 5. radiographic examination using digora intraoral periapical sensor plate and software showing mandibular premolars with (0-2 mm) periapical radiolucency. exclusion criteria: 1. medically compromised patients having significant systemic disorders. (asa iii or iv). 2. history of intolerance to nsaids. 3. teeth with: * immature roots * vital pulp tissues. * association with swelling. * acute peri-apical abscess or acute exacerbation of a chronic abscess. * mobility grade ii or iii. * previously accessed or endodontically treated * deep periodontal pockets more than 4 mm * vertical root fractures, coronal perforation, calcification, and external or internal root resorptions. 4. patients who could not interpret the nrs. 5. patients with diabetes, immune-compromising, and immunosuppression disease and pregnant women were, also, excluded.
the treatment of patients with type 1 diabetes mellitus with autologous tolerogenic dendritic cells

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to determine the safety and tolerability of the administration of tolerogenic dendritic cells in patients with type 1 diabetes mellitus.

the purpose of this study is to determine the safety and tolerability of the administration of autologous monocyte-derived dendritic cells tolerised with vitamin-d3, co-cultivated with mesenchymal stem cell and primed peptides in patients with type 1 diabetes mellitus.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 1 diabetes mellitus * the patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation * written informed consent exclusion criteria: * the presence of any malignant tumor within the last 5 years * acute or chronic diseases in the stage of decompensation * chronic infectious diseases: hiv, viral hepatitis b, c, tuberculosis * patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods * chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol * patients are unable or unwilling to give written informed consent and / or follow research procedures * any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study
biktarvy in treatment-naïve late presenters with hiv-1 infection

Conditions: HIV-1-infection

Summary: the efficacy and safety of biktarvy in treatment-naïve late presenters with hiv-1 infection

hiv epidemic is still severe in china, the estimated number if plwh in hiv is around 1.25 million all of china with an increasing trend of new cases. late presenters with low cd4 t cells and/or with hight viral load should be paid more attention for better treatment and care. as a new combined antiretroviral regimen of integrase inhibitor, b/f/taf was recently approved in us and european and also in china which needs more real world data in china. non-inferiority or advantage of b/f/taf comparing with the first line tdf/3tc/efv for later presenters in china needs to be explored.

Eligibility criteria:
inclusion criteria: 1.ability to understand and sign a written informed consent form 2.18 years old or older 3.confirmed hiv-antibody positive through western blot testing without any previous art 4.cd4 \ 1000 copies/ml 5.estimated glomerular filtration rate (gfr) ≥ 50 ml/min (calculated by ckd-epi) 6.clinical status relatively stable 7.females of childbearing potential must agree to utilize highly effective contraception methods or be non-heterosexually from screening throughout the duration of study treatment and for 30 days following the last dose of study drug. exclusion criteria: 1. a new aids-defining condition diagnosed within the 30 days prior to screening 2. participants experiencing severe organ lesion. 3. positive serum pregnancy test or planned to be pregnant. 4. females who are breastfeeding 5. with carcinoma 6. concomitant medication of immunosuppression or chemoradiotherapy 7. participation in any other interventional clinical trial 8. screening stage find: hb \ 1.5 uln,hepatic transaminases (ast and alt) and alp \> 3 × uln,total bilirubin ≤ 2 x uln. 9. any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements

Keywords: biktarvy hiv-1 infection
condensed digital prolonged exposure for individuals treated within somatic trauma care.

Conditions: Post Traumatic Stress Disorder; Acute Stress Disorder

Summary: the purpose of the study is to investigate the feasibility of implementation aspects, treatment effects and change processes regarding a brief trauma-focused internet-based cbt treatment, for patients who have been treated in trauma care at karolinska university hospital and who exhibit symptoms of psychological consequences of the traumatic event. another aim is to explore factors (predictors, moderators and mediators) that influence the effect of the treatment, in order to better understand who responds to the treatment.

the study is un-controlled with 250 participants that will undergo a brief trauma-focused internet-based cbt treatment, delivered as a three-week treatment comprising of four modules (psychoeducation/rational, in vivo exposure, imaginal exposure and relapse prevention). the primary outcome is the pcl-5. secondary outcomes are level of depression (phq-9), quality of life (wsas) and predictors, moderators and mediators of clinically meaningful change in symptoms, dropout rate, rates of inclusion, attrition, adherence,and negative effects. self-reported, qualitative data from participants will be gathered at treatment completion to capture participants' experiences of participating in the intervention, as well as their views on how to further improve the intervention. the treatment effects will be evaluated using a within-group design with repeated measurements. participants in the study will be will recruited from patients treated in the somatic trauma care at the karolinska university hospital in stockholm, sweden.

Eligibility criteria:
inclusion criteria: * exposed to trauma in the past two months according to criterion a for ptsd in the dsm-5 (exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence). * pcl-5 total sum score\>10 * ≥ 18 years * situated in sweden * signed informed consent exclusion criteria: * other serious comorbidity as primary concern (ongoing substance dependence, untreated bipolar disorder, psychotic symptoms, severe depression, borderline personality disorder, high suicidal risk according to the mini) * unable to read and write in swedish * receiving other psychological trauma-focused treatment * ongoing trauma-related threat (e.g., living with a violent spouse) * not stable dose of antidepressant medication the last two weeks

Keywords: condensed prolonged exposure internet-delivered ptsd trauma early intervention prevention cipe
phase ii/iii randomized, double-blind, placebo-controlled study of dehydroepiandrosterone in women with mild to moderate systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: objectives: i. evaluate the safety and efficacy of synthetic dehydroepiandrosterone (gl701) in women with prednisone-dependent systemic lupus erythematosus. ii. describe the pharmacokinetics of gl701.

protocol outline: this is a randomized, double-blind study. patients are stratified by participating institution. patients are randomly assigned to 1 of 2 doses of oral dehydroepiandrosterone or placebo, administered daily for a minimum of 7 months. a prednisone taper is attempted each month in patients with stable or improving disease. therapy continues until a successful prednisone taper is achieved and sustained for at least 2 months, or until a maximum of 9 months. patients are followed for 1 year after entry.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- systemic lupus erythematosus by american college of rheumatology criteria mild to moderate disease characterized as follows: prednisone dose (or equivalent) 10 to 30 mg/day no daily dose 1 mg/kg or greater no alternate-day regimen failed prednisone taper in last 12 months and dose stable for at least 6 weeks prior to entry or no attempt to taper in last 12 months and dose stable for at least 3 months prior to entry no prior participation in double-blind dehydroepiandrosterone (dhea) study at stanford university --prior/concurrent therapy-- no concurrent immunosuppressants no concurrent participation in other clinical studies no investigational agents within the longer of 30 days or 10 half lives of the agent at least 3 months since the following: adrenocorticotropin hormone androgens cyclophosphamide azathioprine intravenous immune globulin other immunosuppressants at least 1 month since any change in dose of concurrent nonsteroidal anti- inflammatory drugs or hydroxychloroquine --patient characteristics-- no hypersensitivity to dhea or inactive ingredient in dhea, i.e.: cornstarch lactose magnesium stearate no condition that would prevent adequate compliance with study no history of breast cancer or reproductive tract malignancy negative pregnancy test required within 2 weeks prior to entry reliable contraception required of fertile women no estrogen-containing oral contraceptive

Keywords: arthritis & connective tissue diseases immunologic disorders and infectious disorders rare disease systemic lupus erythematosus
management of etonogestrel subdermal implant-related bleeding

Conditions: ESI-related Bleeding

Summary: this is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the mayo clinic and the mayo clinic health system. the goal of the research study is to gather information to determine whether doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (esi), as compared to placebo.

esi is a long-acting reversible contraceptive. though safety and efficacy have been established world wide, only about 1 % of women have been reported to use this method. its use is limited by bleeding pattern changes which result in requests for early removal, most commonly within the first 8 months of use. women ages 18-51 years, choosing esi and who meet eligibility criteria, will be offered enrollment in the study at the time of esi insertion. every effort will be made to insert implanon on the same day as consent unless medically contraindicated. prospective diaries will be completed starting on the date of esi insertion. all participants will be contacted by study personnel 13 weeks after enrollment and queried as to the presence of unacceptable bleeding. bleeding concerns will be objectively assessed using a modification of the pictorial blood loss assessment chart (pblac). participants initiating contact with bleeding concerns at any time after 13 weeks post-esi insertion will be offered treatment randomization at the time of contact. the basis for randomized treatment will be whether the bleeding is considered "unacceptable" to the participant. this is inherently subjective, but constitutes the basis for most removal requests. participants that report unacceptable bleeding at 13 weeks post-esi insertion, and those who call with bleeding concerns anytime after 13 weeks post-esi insertion, will be randomized into one of two groups, doxycycline or matching placebo. participants that do not report unacceptable bleeding will continue to complete diaries and may be eligible for randomized treatment if unacceptable bleeding develops.

Eligibility criteria:
inclusion criteria: * premenopausal women, aged 18-51 years * expressed desire for compliance-independent contraception * no current pregnancy or anticipated desire for childbearing within 3 years of study enrollment and implanon insertion * agreement to participate in all study related procedures and evaluations as documented by a signed informed consent exclusion criteria: * current or prior use of implanon * current long-term use of doxycycline for other indications * known structural uterine abnormalities such as polyp, submucosal leiomyoma * prior permanent sterilization or endometrial ablation * pregnancy or desire for childbearing within 3 years * contraindications to or intolerance of etonogestrel * allergy to or intolerance of doxycycline * inability or unwillingness to complete study related procedures and evaluations

Keywords: implanon etonogestrel subdermal implant nexplanon contraception irregular bleeding menometrorrhagia
clinical study on peg-rhg-csf in mobilizing autologous hematopoietic stem cells

Conditions: Lymphoma

Summary: this study is a randomized controlled, open and multi-center clinical study. patients who meet the selection criteria and do not meet the exclusion criteria are randomly given peg-rhg-csf with a fixed dose of 12mg when white blood cells reach the lowest point, or given rhg-csf with a daily mobilization of 5-10μ g/kg until the collection is completed, so as to evaluate the effectiveness and safety of peg-rhg-csf in mobilizing autologous stem cells for lymphoma and multiple myeloma.


Eligibility criteria:
inclusion criteria: 1. 18-65 years old, regardless of sex; 2. patients with lymphoma and multiple myeloma who need autologous hematopoietic stem cell transplantation; 3. kps score ≥70; 4. creatinine clearance rate ≥ 50ml/min, total bilirubin level \< 1.5mg/dl, alt and ast \< 2 times the upper limit of normal value; 5. absolute neutrophil count (anc)≥1.5×109/l, platelet count ≥80×109/l, hb≥ 75g/l, wbc ≥ 3.0× 109/l; 6. patients can tolerate chemotherapy; 7. no active infection before chemotherapy; 8. the patient voluntarily participated in this trial and signed the informed consent form; 9. the researcher thinks that the subjects can benefit. exclusion criteria: 1. those who have previously received allogeneic or autologous hematopoietic stem cell transplantation; 2. serious or uncontrolled virus infection: hiv, syphilis positive; 3. severe dysfunction of internal organs; 4. severe mental or nervous system diseases; 5. allergic to peg-rhg-csf, rhg-csf and other preparations or proteins expressed in escherichia coli; 6. pregnant or lactating female patients; women of childbearing age refuse to accept contraceptive measures; those who plan to become pregnant during the study period; 7. the researcher judges other subjects who are not suitable to participate.
randomized control trial of l-alanine and placebo in fructose intolerance

Conditions: Dietary Fructose Intolerance

Summary: data suggest that alanine may facilitate the intestinal absorption of fructose in patients with dfi and thereby may decrease gi symptoms. we hypothesize that the ingestion of supplemental l-alanine along with mixed meals or snacks that contain foods with free fructose or high fructose content will decrease gi symptoms in subjects with dietary fructose intolerance by facilitating intestinal absorption of fructose. aim: to investigate the effects of co- administration of equi-molar doses of l-alanine or placebo on the occurrence of gi symptoms in subjects with dietary fructose intolerance, in a randomized, double blind, cross over study. methods: we propose to investigate the effects of co-administration of equi-molar doses of l-alanine or placebo on the occurrence of gi symptoms in 70 subjects with dietary fructose intolerance, in a randomized, double blind, cross over study. data analysis: the primary outcome measure will be a comparison of baseline breath sample values and study visit breath sample values. additionally, we will assess subject-reported occurence and severity of nine gastrointestinal symptoms during the test on a visual analog scale (vas). expected results: we anticipate that dietary fructose intolerance (dfi) symptoms will improve with ingestion of supplemental l-alanine (along with foods containing free fructose or high fructose content). we additionally expect treatment of dfi with administration of l-alanine powder to be more practical than co-ingestion of alanine-rich foods, and more convenient for patients.


Eligibility criteria:
inclusion criteria: 1. age between 18-99 years 2. diagnosis of fructose malabsorption (positive breath test after ingestion of 25 grams of fructose defined as either (a) ≥ 20 ppm rise of breath h2/ch4/both over baseline values or a successive rise of ≥ 5 ppm over baseline and in 3 consecutive breath samples) exclusion criteria: 1. cognitive impairment or any other inability to provide informed consent 2. prisoners 3. gi surgery except appendectomy, cholecystectomy, caesarean section, hysterectomy 4. antibiotics in the previous 6 weeks 5. history of bacterial overgrowth or lactose intolerance 6. major co-morbid illnesses, including chronic pancreatitis, celiac disease, inflammatory bowel disease, diabetes, scleroderma, pseudo-obstruction syndromes etc. 7. known food allergies 8. medication use: opioids, tegaserod, laxatives, enemas 9. an allergy or intolerance to any fiber supplements or other dietary nutritional supplements such as: psyllium (metamucil), maltodextrin, citric acid, and methylcellulose (citrucel). 10. difficulty swallowing
west sweden parkinson objective measurement registry study

Conditions: Parkinson Disease; Parkinsonism; Parkinsonian Disorders

Summary: westports will recruit a randomly selected population consisting of 25% of all individuals with parkinson's disease (icd g209) that have visited any of the seven major outpatient neurology or geriatrics clinics in west sweden (population 1.7m) during a predefined 12 month period between sept 2016 and april 2018. baseline clinical and demographic data will be collected along with a 6 x 24h accelerometry recording using the parkinson kinetigraph (global kinetics). repeated data collections will be made with regular intervals of up to 2 years as long as subjects are alive and willing.

the following data will be collected at baseline: date of birth handedness family history of parkinson's disease time of first motor symptom onset laterality of symptom onset time of diagnosis time of first pharmacological intervention (if applicable) first antiparkinsonian drug the following data will be collected at every visit/update current living conditions current non motor complications current medications hoehn and yahr staging clinical impression of severity index in parkinson's disease (cisi-pd) patient self assessments: pdq8, nms-questionnaire, eq5d-5l, patient reported outcome in parkinson's disease (pro-pd) parkinson kinetigraph (pkg) accelerometry based recording of spontaneous movement patterns over a 6x24h period. the following indices will be extracted: median bradykinesia score (bks), median dyskinesia score (dks), fluctuation dyskinesia score (fds), percent daytime with immobility (pti%), percent daytime with tremor (ptt%). the primary analysis will be descriptive and include demographic composition of the population, clinical characteristics and objective measurement data. in addition to indices a standardized qualitative assessment of pkg recordings will be made to identify motor fluctuations. correlations between clinical ratings, patient reported outcomes, disease duration, age, medication and objective measurement indices will be studied in the prospective phase of the study the development of objective movement recordings will be studied along with the development of clinical ratings and patient reported outcomes.

Eligibility criteria:
inclusion criteria: * medical record with a g209 (parkinson's disease) diagnosis * a visit to one of the participating outpatient clinics in west sweden within the last 6 months * informed consent exclusion criteria: * diagnosis revised before visit.

Keywords: accelerometry parkinson kinetigraph